Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

IMUNON enters CRADA with NCI to advance gene-based immunotherapy

IMUNON (NASDAQ: IMNN) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to support further clinical and non-clinical development of IMNN-001, the...

September 10, 2026

Developments

MolDX issues Bionano proposed LCD

Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics (NASDAQ: BNGO) has announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors...

September 10, 2026

Developments

Ocumetics initiates patient recruitment for next-gen lens study

Ocumetics Technology (TSXV: OTC; OTCQB: OTCFF; FRA: 2QBO) has announced that its clinical facility in Mexico City has initiated the patient recruitment process for Group Two of the company’s ongoing human clinical...

September 8, 2026

Developments

eXoZymes selects Curia as CDMO for NCT

eXoZymes (NASDAQ: EXOZ) has entered into an agreement with closely held contract research, development, and manufacturing organization (CDMO) Curia Global to initiate technology transfer and scale-up activities for N...

September 8, 2026

Developments

Polyrizon completes site contracts for NASARIX first-in-human allergy study

Polyrizon (NASDAQ: PLRZ) has completed contracting with the fourth and fifth U.S. clinical sites participating in its study of NASARIX Allergy Blocker (PL-14), moving the program into study execution. The planned first...

September 2, 2026

Developments

cbdMD to acquire Twinlab brands

cbdMD (NYSE American: YCBD) has announced that it has entered into a definitive asset purchase agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea...

September 2, 2026

Developments

USPTO issues NOA for Purple’s next-gen multispecific antibody platform

Purple Biotech (NASDAQ/TASE: PPBT) has announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent application covering tri-specific antibody constructs and methods of use...

September 2, 2026

Developments

Karyopharm submits sNDA for XPOVIO + ruxolitinib in MF

Karyopharm Therapeutics (NASDAQ: KPTI) has announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA seeking accelerated approval for XPOVIO (selinexor) in combination with ruxolitinib for...

August 31, 2026

Developments

TELA announces COO/CFO transition and cost reduction

TELA Bio (NASDAQ: TELA) has announced that Roberto Cuca, chief operating officer and chief financial officer (COO/CFO), will step down from the role effective today. In a statement, Heather Getz, CEO of TELA, commented...

August 31, 2026

Developments

Aprea announces IP expansion for precision oncology programs

Aprea Therapeutics (NASDAQ: APRE) has announced an expansion of its intellectual property (IP) portfolio for precision oncology programs. According to Aprea, the company has strengthened its global IP portfolio with 28...

August 28, 2026

Developments

Quoin reports positive interim data from study of topical treatment for NS

Quoin Pharmaceuticals (NASDAQ: QNRX) has announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome (NS), a rare, genetic skin disease...

August 28, 2026

Developments

BrainsWay Deep TMS study shows 70% reduction in suicidal ideation in MDD

BrainsWay (NASDAQ: BWAY; TASE: BWAY) has announced the publication of new peer-reviewed data in the Journal of Affective Disorders demonstrating significant reductions in suicidal ideation among patients with major...

August 27, 2026

Developments

Precision doses first patient in study of in vivo gene editing program in DMD

Precision Biosciences (NASDAQ: DTIL) has announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating its in vivo gene editing program, PBGENE-DMD, for the treatment of...

August 25, 2026

Developments

RMTG’s Cellgenic launches NK cell product line outside U.S.

Regenerative Medical Technology Group (RMTG) (OTCID: RMTG) has announced that its Cellgenic division has launched a natural killer (NK) cell product line for permitted markets outside the U.S., with an initial...

August 25, 2026

Developments

VERAXA and Secarna report positive results from AOC research collaboration

VERAXA Biotech (NASDAQ: VRXA) and closely held Secarna Pharmaceuticals have announced positive initial results from their research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for...

August 25, 2026

Developments

Oculis treats first patient in trial of Privosegtor in ON

Oculis Holding (NASDAQ: OCS; XICE: OCS) has announced that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON). According to Oculis...

August 25, 2026

Developments

Activist hedge fund, Kaos Capital, calls for a Capricor Therapeutics strategic shift

Kaos Capital today issued a letter to its fellow Capricor Therapeutics (NASDAQ: CAPR) shareholders calling on them to support an immediate meeting with the Board of Directors regarding the Company’s future strategic...

August 21, 2026

Developments

Niagen expands Tru Niagen retail footprint

Niagen Bioscience (NASDAQ: NAGE) has announced that Tru Niagen, the company’s healthy-aging coenzyme nicotinamide adenine dinucleotide (NAD+)-boosting supplement, is now available at U.S. GNC and Sam’s Club retail...

August 20, 2026

Developments

Protagenic receives FDA pre-IND feedback for neuropeptide in GAD

Protagenic Therapeutics (OTCQB: PTIX) has announced that it has received written responses from the FDA to its Type B pre-Investigational New Drug (pre-IND) meeting request for PT00114, the company’s leading...

August 20, 2026

Developments

Revive to build biodefence and pandemic preparedness portfolio

Revive Therapeutics (OTCQB: RVVTF; CSE: RVV; Frankfurt: 31R) has outlined its strategy to build a focused biodefence and pandemic preparedness medical-countermeasure portfolio led by bucillamine, a thiol-based drug with...

August 19, 2026

Developments

Sunshine receives approval for generic Enalapril in Canadian market

Sunshine BioPharma (NASDAQ: SBFM) has announced Canadian regulatory approval of its generic ACE inhibitor, Enalapril, in oral tablets of 2.5mg, 5mg, 10mg and 20mg for the treatment of hypertension, heart failure, and...

August 19, 2026

Developments

Revelation selects Avance Clinical as CRO for TITAN study

Revelation Biosciences (NASDAQ: REVB) has announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design...

August 19, 2026

Subscribe